Cargando…

Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma

Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Junjie, Zhou, Kai, Lv, Dongxiao, Wu, Changshun, Feng, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168362/
https://www.ncbi.nlm.nih.gov/pubmed/35677433
http://dx.doi.org/10.3389/fphar.2022.714408
_version_ 1784720991610470400
author Teng, Junjie
Zhou, Kai
Lv, Dongxiao
Wu, Changshun
Feng, Hong
author_facet Teng, Junjie
Zhou, Kai
Lv, Dongxiao
Wu, Changshun
Feng, Hong
author_sort Teng, Junjie
collection PubMed
description Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of an Asian woman diagnosed with stage IV lung adenocarcinoma harboring an ERBB2 mutation. She received Nivolumab treatment when her disease progresses after previous chemotherapy and Afatinib treatment. However, the patient did not response to Nivolumab. PTEN mutation was detected by next-generation sequencing (NGS) after treatment with Nivolumab. PTEN, a secondary mutation, may be served as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma. The relationship between PTEN mutation and immunotherapy is complex and needs further study.
format Online
Article
Text
id pubmed-9168362
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91683622022-06-07 Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma Teng, Junjie Zhou, Kai Lv, Dongxiao Wu, Changshun Feng, Hong Front Pharmacol Pharmacology Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of an Asian woman diagnosed with stage IV lung adenocarcinoma harboring an ERBB2 mutation. She received Nivolumab treatment when her disease progresses after previous chemotherapy and Afatinib treatment. However, the patient did not response to Nivolumab. PTEN mutation was detected by next-generation sequencing (NGS) after treatment with Nivolumab. PTEN, a secondary mutation, may be served as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma. The relationship between PTEN mutation and immunotherapy is complex and needs further study. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9168362/ /pubmed/35677433 http://dx.doi.org/10.3389/fphar.2022.714408 Text en Copyright © 2022 Teng, Zhou, Lv, Wu and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Teng, Junjie
Zhou, Kai
Lv, Dongxiao
Wu, Changshun
Feng, Hong
Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
title Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
title_full Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
title_fullStr Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
title_full_unstemmed Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
title_short Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
title_sort case report: pten mutation induced by anti-pd-1 therapy in stage iv lung adenocarcinoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168362/
https://www.ncbi.nlm.nih.gov/pubmed/35677433
http://dx.doi.org/10.3389/fphar.2022.714408
work_keys_str_mv AT tengjunjie casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma
AT zhoukai casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma
AT lvdongxiao casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma
AT wuchangshun casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma
AT fenghong casereportptenmutationinducedbyantipd1therapyinstageivlungadenocarcinoma